In the antithrombotic trialists' collaboration overview in patients at risk of ischemic cardiovascular events, antiplatelet therapy did not reduce the odds of a vascular event in diabetes (−7%), different from the highly significant reduction produced in the overall population at risk (−25%) ( 9 ).
← all excerpts
Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.
1
—
—